{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T02:06:27Z","timestamp":1649124387918},"reference-count":6,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2020,12,1]]},"DOI":"10.1001\/jamadermatol.2020.3341","type":"journal-article","created":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T16:46:58Z","timestamp":1604508418000},"page":"1381","source":"Crossref","is-referenced-by-count":0,"title":["Potential Role for Topical Antiandrogens in the Management of Acne Among Patients Receiving Masculinizing Hormone Therapy\u2014Reply"],"prefix":"10.1001","volume":"156","author":[{"given":"Diane","family":"Thiboutot","sequence":"first","affiliation":[{"name":"The Pennsylvania State University College of Medicine, Hershey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Cartwright","sequence":"additional","affiliation":[{"name":"Cassiopea Inc, San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Mazzetti","sequence":"additional","affiliation":[{"name":"Cassiopea SpA, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"6","key":"dlr200005r2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jamadermatol.2020.0465","article-title":"Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials.","volume":"156","author":"Hebert","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"1","key":"dlr200005r3","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/jsm.12366","article-title":"Short- and long-term clinical skin effects of testosterone treatment in trans men.","volume":"11","author":"Wierckx","year":"2014","journal-title":"J Sex Med"},{"key":"dlr200005r5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2020.05.086","article-title":"Eligibility criteria related to hormone therapy in acne clinical trials: a systematic review.","author":"DeGrazia","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"12","key":"dlr200005r6","first-page":"16","article-title":"Hormonal treatment of acne in women.","volume":"2","author":"Ebede","year":"2009","journal-title":"J Clin Aesthet Dermatol"},{"key":"dlr200005r1","year":"2020"},{"key":"dlr200005r4","unstructured":"US Food and Drug Administration. Guidance for industry on acne vulgaris: developing drugs for treatment; availability. Accessed May 5, 2020. https:\/\/www.federalregister.gov\/documents\/2005\/09\/19\/05-18512\/draft-guidance-for-industry-on-acne-vulgaris-developing-drugs-for-treatment-availability"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2772467\/jamadermatology_thiboutot_2020_lr_200005_1607046279.57931.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T01:22:29Z","timestamp":1607563349000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2772467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":6,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.3341","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,1]]}}}